Vicore Pharma to Join Chardan Healthcare Conference Panel on Respiratory Disease
Vicore Pharma Holding AB said it will take part in the Chardan Healthcare Conference on October 20, 2026, at the Lotte New York Palace in New York. The company will join a panel on idiopathic pulmonary fibrosis and chronic respiratory disease innovation and hold one-on-one meetings. Its lead oral candidate, buloxibutid, is being tested in the Phase 2b ASPIRE trial for IPF and has received FDA Orphan Drug and Fast Track designations.
Vicore Pharma Holding AB will attend the Chardan Healthcare Conference in New York on October 20, 2026. Its representatives are scheduled for a panel discussion and individual meetings at the Lotte New York Palace.
The panel will cover innovation in idiopathic pulmonary fibrosis and chronic respiratory conditions, including antifibrotics, cystic fibrosis, bronchiectasis, and COPD. Vicore's oral candidate buloxibutid is in the global 52-week Phase 2b ASPIRE study for IPF and holds FDA Orphan Drug and Fast Track designations.
If buloxibutid advances, patients with IPF and other chronic respiratory conditions could gain another oral treatment option, potentially affecting disease management and quality of life. Clinicians and caregivers may see changed care discussions, while investors and the biopharma sector may watch trial results as signals for similar therapies. These are early-stage possibilities; conference participation alone does not establish efficacy or access.